In our study, GEPIA analysis revealed that EIF4E expression is significantly increased in GBM, and survival analysis showed that glioma patients with high EIF4E expression had shorter overall survival and disease-free survival, indicating that EIF4E, like PBK, could be regarded as a biomarker for glioma. This evidence concerns the gene EIF4E and central nervous system cancer.